Skip to main content

Impact BioMedical Inc.

corporate_fare Company Profile

Impact BioMedical Inc.

IBO·NYSE·Life Sciences·CIK 0001834105

Impact Biomedical Inc. discovers, confirms, and patents unique science and technologies that can be developed into new offerings in human healthcare and wellness in collaboration with external partners through licensing, co-development, joint ventures, and other relationships. It trades on the NYSE American under ticker symbol IBO. By leveraging technology and new science with strategic partnerships, the company provides advances in biopharmaceuticals, over the counter direct to consumer wellness offerings, and drug discovery for the prevention, inhibition, and treatment of neurological, oncologic, and inflammatory diseases. Its business model includes partnering and potentially direct sales for commercialization and distribution. Potential licensors and development partners include pharmaceutical, consumer packaged goods companies and others, who would commercialize IBO technologies in exchange for milestone and royalty payments. Operations are conducted, and assets are owned, through principal subsidiaries: Global BioLife, Inc. (incorporated April 14, 2017), Impact BioLife Science, Inc. (incorporated August 28, 2020), Global BioMedical, Inc. (incorporated April 18, 2017), and Sweet Sense, Inc. (incorporated April 30, 2018). Impact Biomedical is the sole owner of the issued and outstanding common stock of Impact BioLife Science, Inc.; owns 90.9% of Global Biomedical, Inc. issued and outstanding common stock; through majority owned subsidiary Global Biomedical, Inc., owns 81.8% of the issued and outstanding common stock of Global BioLife, Inc.; and owns approximately 95.5% of the issued and outstanding common stock of Sweet Sense. Impact BioMedical has several unique and proprietary technologies that are in continuing development.

Impact BioMedical Inc. (NYSE:IBO) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 3 items for IBO at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 9/10. Across its 3 most recent items scored 7 or higher, the top rating is 9/10, with 3 rated 8 or above. Recent SEC coverage for IBO spans 8-K, 10-Q.

Recent high-impact activity:

  • Impact BioMedical Closes Zoar Merger; IBO Delisted, PubCo Trades as ZOAR
  • Impact BioMedical Shareholders Approve Zoar Merger With 99.97% of Votes Cast
  • Impact BioMedical 10-Q: Going Concern Warning With Just $21,000 Cash on Hand

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$32K
Net Income
-$11.84M
Diluted EPS
-$0.38
Op. Cash Flow
-$1.89M
Gross Profit
-$392K
Operating Income
-$4.28M
Cash & Equivalents
$3K
Debt / Equity
0.00×
Net Margin
-369.94×
Shares Outstanding
104.62M sh
Source: 10-K · filed 2026-03-11 · accession 0001493152-26-009711

Short Interest & Short Volume

1.15 days to cover

FINRA reported short interest of 24,619 shares in IBO as of the October 30, 2026 settlement, a 6.4% decrease from the prior period — about 1.1 days to cover at its recent average daily volume. On November 17, 2026, 42.4% of IBO volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)24,619 shares as of October 30, 2026
Change vs prior period▼ 6.4%
Days to cover1.15 at avg daily volume of 21,408
Daily short volume (FINRA facilities)42.4% of 8,578 shares on November 17, 2026
5-day average short volume52.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with I →
$5.25
Market cap
$53.31M
Volume
25.5K (1.6× avg)
3-mo avg 15.9K
Last traded · 2026-11-18

show_chartPrice Chart

Loading chart...

feed IBO - Latest Insights

IBO
Nov 18, 2026, 10:06 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $5.25
Real-time Price: $5.25 info
Change: $0 (0%) info
Market Cap: $53.309M info
IBO
Nov 17, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $6.17
Real-time Price: $5.25 info
Change: -$0.9204 (-15%) info
Market Cap: $53.309M info
IBO
Nov 09, 2026, 4:50 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.33
Real-time Price: $5.25 info
Change: +$0.9196 (+21%) info
Market Cap: $53.309M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets